Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL

Dr Matthew Davids - Dana-Farber Cancer Institute, Boston, USA
Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL ( Dr Matthew Davids - Dana-Farber Cancer Institute, Boston, USA )
18 Jun 2026

Selinexor plus ruxolitinib improves spleen response and survival in Janus kinase inhibitor naïve myelofibrosis

Prof Claire Harrison - Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Selinexor plus ruxolitinib improves spleen response and survival in Janus kinase inhibitor naïve myelofibrosis ( Prof Claire Harrison - Guy’s and St Thomas’ NHS Foundation Trust, London, UK )
18 Jun 2026

Fatigue in adult ITP is common despite adequate platelet counts and minimal bleeding

Prof David Kuter - Harvard Medical School, Boston, USA
Fatigue in adult ITP is common despite adequate platelet counts and minimal bleeding ( Prof David Kuter - Harvard Medical School, Boston, USA )
18 Jun 2026

Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma

Prof Chan Cheah - Sir Charles Gairdner Hospital, Perth, Australia
Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma ( Prof Chan Cheah - Sir Charles Gairdner Hospital, Perth, Australia )
18 Jun 2026

Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19

Dr Frederick Chen - Barts Health NHS Trust, London, UK
Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19 ( Dr Frederick Chen - Barts Health NHS Trust, London, UK )
18 Jun 2026

Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL

Prof Anthony Moorman - Newcastle University, Newcastle, UK
Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )
18 Jun 2026

Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma

Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy
Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma ( Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy )
18 Jun 2026

Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma

Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy
Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma ( Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy )
18 Jun 2026

Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival

Prof Martin Schrappe - Universitätsklinikum Schleswig-Holstein, Kiel, Germany
Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival ( Prof Martin Schrappe - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )
18 Jun 2026

Gabapentin plus tramadol reduces opioid escalation for mucositis pain in head & neck cancer

Dr Minit Shah - Tata Memorial Centre, Mumbai, India
Gabapentin plus tramadol reduces opioid escalation for mucositis pain in head & neck cancer ( Dr Minit Shah - Tata Memorial Centre, Mumbai, India )
17 Jun 2026

Metronomic chemo plus nivolumab (TMC-I) improves survival in R/M head & neck cancer vs platinum chemotherapy

Dr Minit Shah - Tata Memorial Centre, Mumbai, India
Metronomic chemo plus nivolumab (TMC-I) improves survival in R/M head & neck cancer vs platinum chemotherapy ( Dr Minit Shah - Tata Memorial Centre, Mumbai, India )
17 Jun 2026

Understanding patient expectations and clinicians' goals in favourable risk aRCC patients

Prof Daniele Santini and Dr Yann Alexandre Vano
Understanding patient expectations and clinicians' goals in favourable risk aRCC patients ( Prof Daniele Santini and Dr Yann Alexandre Vano )
15 Jun 2026